- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02087332
Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics.
Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Grigory P Arutyunov, Prof
- Phone Number: 007(495)952-73-77
- Email: arut@ossn.ru
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women in the age from 40 to 70 years.
- Established diagnosis of II-III grade essential arterial hypertension
- NYHA II-III chronic heart failure
- Salt-sensitivity
- Stable therapy for 3 months prior enrollment to the study including any diuretic, ACE-inhibitor, beta-blocker.
- Signed informed consent for participation in the study.
- Women with child-bearing potential should agree to use effective birth control methods from screening up to completion of the study, excluding situations when their sexual partner(s) are surgically sterilized, or whеn women do not have any sexual contacts. Effective methods of birth control are contraception methods which are used constantly and regularly (including implantable contraceptives, injectable contraceptives, oral contraceptives, transdermal contraceptives, intrauterine devices, diaphragms with spermicides, male or female condoms or cervical cap).
Exclusion Criteria:
- Unlikely cooperation with a patient in the study period, disability
- Identification of salt - resistance at screening
- Patients that have had myocardial infarction, unstable angina pectoris, percutaneous coronary intervention heart failure, hypertensive encephalopathy, cerebrovascular accident (stroke) or transient ischaemic attack for the last 3 months.
- Patients with severe heart failure (Stage IV of New York Heart Association), clinically significant aortic valve or mitral stenosis, uncorrected coarctation of the aorta, obstruction of cardiac output (obstructive hypertrophic cardiomyopathy)
- Previous glomerulonephritis, severe pyelonephritis or another known severe renal disease which is confirmed by GFR < 40 ml/min/1.73 m2 calculated by Cockroft-Gault formula.
- Secondary arterial hypertension, severe or uncontrolled AH at the study enrollment (BP> 180 mm Hg or DAP > 110 mm Hg)
- Any severe, decompensated or unstable diseases or conditions which, on the investigator's opinion, endanger patient's life or aggravate disease prognosis (decompensated heart failure, anemia, severe diabetes mellitus, autoimmune, oncological diseases, hepatic, allergic reactions, connective tissue diseases, etc.)
- Acute infectious diseases.
- Hypersensitivity to components of Britomar or Diuver
- Pregnancy, lactation period.
- Participation in another clinical study for the last 30 days.
- Scheduled coronary artery surgery (for example, stent implantation or coronary artery bypass grafting) or any other non-cardiological major surgery.
- 13. Administration of drugs which affect natriuresis level (any diuretics which are not related with the study product). Patients are excluded from the study if they have taken the drugs for the last 48 years up to Visit D -10, in the screening period and/or treatment period/follow-up period of the study.
- Use of narcotic drugs or alcohol abuse for the last 6 months and inability/unwillingness to refrain from narcotic drugs and excessive alcohol intake in the study period. The excessive alcohol intake is average alcohol >2 units of alcohol. A unit of alcohol for various beverages is 12 ounce (350 ml) of beer, 5 ounce (150 ml) of wine or 1.5 ounce (45 ml) of 80% alcohol.
- Any other reason which would hinder patients' compliance with study requirements or their understanding of the study aim and potential risks of participation in study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prolonged release Torasemide (Britomar)
Prolonged release Torasemide (Britomar) - round, biconvex, white to off-white tablets debossed SN with one side. 1 tablet contains active substance - torasemide 5 or 10 mg and excipients - guar gum, maize starch, anhydrous colloidal silica, magnesium stearate, lactose. Dosage scheme: per os, once a day, regardless of meals. The common starting dose in CHF - 10-20 mg once a day. If adequate diuretic effect is absent, the dose is increased approximately twofold up to adequate diuretic effect. |
|
Active Comparator: Torasemide (Diuver)
Torasemide (Diuver) - white to off-white, round, biconvex tablets. 1 tablet contain active substance - torasemide 5 or 10 mg and excipients - lactose monohydrate, maize starch, sodium glycolate starch, anhydrous colloidal silica, magnesium stearate.
Dosage scheme: per os, once a day, after meals.
Therapeutic dose - 5 mg a day.
If necessary, a dose may be increased up to 20 mg a day, in some cases - up to 40 mg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inflammatory markers excretion
Time Frame: 3 months
|
15% or more increasing of the following Tamm-Horsfall protein, beta-2-microglobulin, osteoponin, TGF- β1 excretion in comperison with baseline level
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily sodium excretion
Time Frame: 3 months
|
Increasing of daily sodium excretion on 30% or more in comparison with baseline
|
3 months
|
Augmentation index
Time Frame: 3 months
|
Decreasing of augmentation index on 30 or more percents in comparison with baseline level
|
3 months
|
Albuminuria
Time Frame: 3 months
|
Appearance of albuminuria of any stage or increasing of albuminuria level in case of existing albuminuria at the baseline.
(measured by dipstick)
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Grigory P Arutyunov, Prof, Russian Society for Heart Failure
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Heart Failure
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Sodium Potassium Chloride Symporter Inhibitors
- Torsemide
Other Study ID Numbers
- TOR-IIT-001 (Other Grant/Funding Number: Investigator Initiated study. Grant was provided by Takeda Pharmaceuticals LLC, Russia)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Heart Failure
-
Maastricht University Medical CenterUniversity College Dublin; RWTH Aachen University; Queen's University, BelfastCompletedChronic Heart FailureNetherlands, Germany, Ireland, United Kingdom
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Jordan Cardio Vascular Research GroupRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureJordan
-
Lithuanian University of Health SciencesCompletedHeart Failure | Chronic Heart Failure | Congestive Heart Failure | Right Ventricular FailureLithuania
-
Zensun Sci. & Tech. Co., Ltd.RecruitingChronic Heart FailureChina
-
University Hospital, Clermont-FerrandHospices Civils de Lyon; University Hospital, Grenoble; Hôpital de la Croix-Rousse and other collaboratorsRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureFrance
-
University of Roma La SapienzaUnknownChronic Heart Failure | Decompensated Heart Failure | Morality
-
University Medicine GreifswaldDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)RecruitingChronic Heart FailureGermany
-
AquaPass Medical Ltd.CompletedChronic Heart FailureIsrael
-
University Hospital, Gentofte, CopenhagenUnknownChronic Heart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVDenmark
Clinical Trials on Prolonged release Torasemide (Britomar)
-
Ferrer Internacional S.A.Completed
-
Ferrer Internacional S.A.Completed
-
Max Zeller Soehne AGCompleted
-
GlaxoSmithKlineCompleted
-
Boehringer IngelheimCompleted
-
Joint Stock Company "Farmak"Completed
-
Mundipharma Research GmbH & Co KGCompletedPain | ConstipationUnited Kingdom
-
Joint Stock Company "Farmak"Completed
-
Mundipharma Research GmbH & Co KGCompletedChronic OsteoarthritisSpain, Belgium, Finland, Czechia, Germany, Hungary
-
Gedeon Richter Plc.Completed